Parallax Volatility Advisers’s Clovis Oncology, Inc. CLVS Stock Holding History

Parallax Volatility Advisers’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-86,340	Closed	-$174K	–	3474
2022 Q1	$174K	Buy	86,340 +48,010	+125%	+$94.3K	﹤0.01%	2227
2021 Q4	$104K	Sell	38,330 -2,693	-7%	-$9.96K	﹤0.01%	2596
2021 Q3	$183K	Sell	41,023 -6,762	-14%	-$32.6K	﹤0.01%	2528
2021 Q2	$277K	Buy	+47,785	New	+$280K	﹤0.01%	2376
2019 Q4	–	Sell	-264,320	Closed	-$1.92M	–	2730
2019 Q3	$1.04M	Buy	+264,320	New	+$2.14M	﹤0.01%	1360
2019 Q1	–	Sell	-70,291	Closed	-$1.76M	–	4332
2018 Q4	$1.26M	Buy	70,291 +48,453	+222%	+$990K	﹤0.01%	1227
2018 Q3	$641K	Buy	+21,838	New	+$845K	﹤0.01%	1379
2018 Q1	–	Sell	-8,067	Closed	-$549K	–	4717
2017 Q4	$549K	Sell	8,067 -16,095	-67%	-$1.13M	﹤0.01%	1476
2017 Q3	$1.99M	Buy	24,162 +23,769	+6,048%	+$1.88M	﹤0.01%	849
2017 Q2	$37K	Buy	393 +371	+1,686%	+$22.7K	﹤0.01%	1853
2017 Q1	$1K	Buy	+22	New	+$1.34K	﹤0.01%	3444
2016 Q4	–	Sell	-12,230	Closed	-$430K	–	4424
2016 Q3	$441K	Buy	+12,230	New	+$262K	﹤0.01%	1540
2016 Q1	–	Sell	-1,000	Closed	-$35K	–	3972
2015 Q4	$35K	Buy	+1,000	New	+$64.5K	﹤0.01%	2433

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Parallax Volatility Advisers's CLVS Position: Q2 2022 in Review

Parallax Volatility Advisers sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 86,340 shares — an estimated $174K sold.

Parallax Volatility Advisers first reported a position in CLVS in Q4 2015 and held it in 13 quarters. The position peaked at $1.99M in Q3 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

Parallax Volatility Advisers reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 86,340 Clovis Oncology, Inc. shares in Q2 2022, an estimated $174K.
Parallax Volatility Advisers first reported a position in Clovis Oncology, Inc. in Q4 2015 and held it in 13 quarters.
Parallax Volatility Advisers's Clovis Oncology, Inc. position peaked at $1.99M in Q3 2017.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Parallax Volatility Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.